{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}],"title":"PR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"}],"units":"Participants"}],"description":"OR is defined as the number of participants with evidence of CR (disappearance of all target lesions. Any pathological lymph node must be less than 10 millimeters in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator in participants following cross-over to Trametinib. The evaluation was carried out by the Investigator per RECIST, Version 1.1. Cross-over Population included the subset of participants who were randomized to CT and who elected to cross-over to Trametinib following disease progression on CT. Only participants who received at least one dose of Trametinib were included in this population.","groups":[{"description":"Participants randomized to chemotherapy and who did not receive subsequent anti-cancer therapy after discontinuing chemotherapy were allowed to cross-over to Trametinib and received 2 mg tablet once daily until disease progression, death or withdrawal.","id":"OG000","title":"Cross-over From Chemotherapy to Trametinib"}],"paramType":"NUMBER","populationDescription":"Cross-over Population","reportingStatus":"POSTED","timeFrame":"Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)","title":"Number of Participants With OR Following Cross-over to Trametinib","type":"SECONDARY","unitOfMeasure":"Participants"}